AegirBio logo

AegirBio Investor Relations Material

AegirBio AB, a diagnostic company, develops and commercializes tests to follow the dosage of biological drugs. AegirBio's main product is the Oncolynx®, a urine test to be used with treatment of colorectal cancer patients. The test measures the levels of the drug in the bloodstream. This helps physicians optimize the dosage to achieve effective and safe treatment of cancer with biological drugs. The company was incorporated in 2019 and is based in Lund, Sweden

Upcoming events for

Q2 20222022-08-25

Latest company events

Ticker symbol




About the company

Dig deeper into the AegirBio fundamentals on Quartr.

  • Skip straight to the Q&A session
  • Receive notifications about new events
  • Connect the financial calender on your phone
  • Figure out why the stock is up or down
  • Read the transcripts or scroll the deck
  • Access earnings or press releases
App store link
Android play link
Quartr app screenshot